Last quarter (Q2 2022), E Therapeutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, E Therapeutics's net income was £―. See E Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Jan 23	Jan 22	Jan 21	Jan 20	Jan 19
Total Revenue	-	£ 475.00K	£ 477.00K	£ 317.00K	£ 456.00K	£ 44.00K
Cost of Revenue	-	-	-	£ 0.00	£ 0.00	£ 0.00
Gross Profit	-	£ 475.00K	£ 477.00K	£ 317.00K	£ 456.00K	£ 44.00K
Operating Expense	-	£ 10.71M	£ 10.04M	£ 4.80M	£ 3.34M	£ 5.16M
Operating Income	-	£ -10.24M	£ -9.57M	£ -4.49M	£ -2.89M	£ -5.11M
Net Non Operating Interest Income Expense	-	£ 219.00K	£ 51.00K	£ 17.00K	£ 15.00K	£ 29.00K
Other Income Expense	-	£ -248.00K	-	-	-	-
Pretax Income	-	£ -9.77M	£ -9.52M	£ -4.47M	£ -2.87M	£ -5.08M
Tax Provision	-	£ -1.50M	£ 1.45M	£ -784.00K	£ -526.00K	£ -1.09M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -8.27M	£ -10.96M	£ -3.68M	£ -2.35M	£ -4.00M
Basic EPS	-	-	£ -0.02	£ >-0.01	£ >-0.01	£ -0.01
Diluted EPS	-	-	£ -0.02	£ >-0.01	£ >-0.01	£ -0.01
Basic Average Shares	-	£ 537.35M	£ 488.34M	£ 373.22M	£ 268.86M	£ 268.58M
Diluted Average Shares	-	£ 537.35M	£ 488.34M	£ 373.22M	£ 268.86M	£ 268.58M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	£ 51.00K
Total Expenses	-	£ 10.71M	£ 10.04M	£ 4.80M	£ 3.34M	£ 5.16M
Net Income From Continuing And Discontinued Operation	-	£ -8.27M	£ -10.96M	£ -3.68M	£ -2.35M	£ -4.00M
Normalized Income	-	£ -11.27M	£ -7.71M	£ -3.68M	£ -2.35M	£ -4.00M
Interest Expense	-	-	-	£ 0.00	-	-
EBIT	-	£ -9.75M	£ -9.51M	£ -4.47M	£ -2.89M	£ -5.11M
EBITDA	-	£ -9.28M	£ -9.29M	£ -4.36M	£ -2.79M	£ -5.04M

Currency in GBP

E Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing